Audience

Read by all 50 of the biggest Pharma companies, like Pfizer and Novartis, as well as thousands of innovative, clinical-stage biotechs.

OUR PLATFORMS draw

256k+
daily email subscribers
700K+
unique monthly visitors
1.9M
average monthly page views
70K+
event registrations

OUR SUBSCRIBERS count

OUR SUBSCRIBERS span

OUR TOP STORIES include

Three deaths in CAR-T trials prompt halt by Novartis; Bristol Myers programs also paused
August 31, 2026
Updated: Novartis sinks after second disastrous trial failure, this time of Avidity-acquired drug
September 8, 2026
Biotech's most exciting startups of 2026: Meet this year's Endpoints 11
September 25, 2026
Expanding its biopharma plans, Anthropic looks for a life sciences dealmaker
September 8, 2026
Deaths in Novartis CAR-T trial force a reckoning over acceptable risk in autoimmune disease
September 2, 2026

Get started

Connect with us to request a media kit and learn more about rates and availability.

Julie O'Meara
Julie O'Meara
Vice President, Brand Partnerships, Endpoints News
Melissa Nazzaro